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BULLET STATEMENTS 
 
 Psoriasiform and eczematous lesions are the most common skin adverse 
events of anti-TNF- treatment, yet their immune profile remains to be 
elucidated. 
 We found that these lesions are distinct from genuine psoriasis and eczema, 
but are uniformly characterized by a strong Th1 inflammatory signature. 
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 Results might help to guide future treatment strategies for chronic 
inflammatory diseases preventing these skin side effects. 
 
ABBREVIATIONS 
CAMP  Cathelicidin antimicrobial peptide 
DEFB4 Defensin, Beta 2 
HE  Hematoxylin Eosin 
HPSS  Histopathologic psoriasis severity score 
IBD  Inflammatory bowel disease 
NOS2  Nitric Oxide Synthase 2 (inducible Nitric Oxide Synthase/iNOS) 
pDC  Plasmacytoid dendritic cell 
RA  Rheumatoid arthritis 
 
 
ABSTRACT 
 
Background: Psoriasiform and eczematous eruptions are the most common 
dermatological adverse reaction linked to anti-TNF- therapy. Yet, a detailed 
characterization of their immune phenotype is lacking. 
Objectives: We sought to characterize anti-TNF- induced inflammatory skin 
lesions on a histopathologic, cellular and molecular level, compared to psoriasis, 
eczema (atopic dermatitis), and healthy control skin. 
Methods: Histopathologic evaluation, gene expression (quantitative RT-PCR) and 
computer-assisted immunohistologic studies (TissueFAXS) were performed on 19 
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skin biopsies from IBD (n=17) and rheumatoid arthritis (n=2) patients with new-onset 
inflammatory skin lesions during anti-TNF--therapy. 
Results: While most biopsies showed a psoriasiform and/or spongiotic 
(eczematous) histopathologic architecture, these lesions were inconsistent with 
either psoriasis or eczema on a molecular level using an established CCL27/iNOS 
classifier. Despite some differences in immune skewing depending on the specific 
histopathologic reaction pattern, all anti-TNF--induced lesions showed strong IFN-γ 
activation, at higher levels than in psoriasis or eczema. IFN-γ was most likely 
produced by CD3/CD4/Tbet-positive Th1 lymphocytes.  
Conclusions: New-onset anti-TNF--induced eruptions previously classified as 
psoriasis or spongiotic dermatitis (eczema) exhibit a molecular profile that is different 
from either of these disorders. 
 
KEYWORDS: anti-TNF; TNF-alpha; psoriasiform; eczematous; psoriasis; eczema; 
 
INTRODUCTION 
Anti-tumor necrosis factor alpha (TNF-) antibodies are efficacious therapeutics for 
chronic inflammatory diseases such as Crohn’s disease, ulcerative colitis, 
rheumatoid arthritis (RA) and psoriasis, with an overall favorable safety profile.1 
Psoriasiform and eczematous skin eruptions have turned out to be the most frequent 
inflammatory skin complications of TNF--blocker treatment,2-6 with a cumulative 
incidence of 28.9% at 10 years, leading to anti-TNF- discontinuation in 18.6% of 
patients.5 After switching to a different TNF--blocker, a recurrence rate of 57% was 
observed, suggesting a class effect.5 While TNF--blockers increase blood 
eosinophil levels7 and worsen pre-existing eczema,8,9 the advent of psoriasiform 
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lesions came as a surprise,10 as TNF--blockers are generally a well-established 
anti-psoriatic treatment modality.11 Currently, psoriasiform lesions are classified as 
“classic” psoriasiform, inverse, palmoplantar, palmoplantar pustular, guttate, and 
scalp psoriasiform lesions.12 Eczematous lesions, which are histologically 
characterized by a spongiotic inflammatory reaction (spongiotic dermatitis), have not 
been further classified.8 Other inflammatory cutaneous side effects include lupus-like 
disorders, vasculitis, and granulomatous and lichenoid reactions, but these appear at 
much lower frequencies.13  
A disturbed Th1/Th2 balance has been postulated as the basis for eczematous 
lesions,14 suggesting TNF- as an important Th1 component that can suppress Th2 
responses,8 with Th2 cytokines driving the formation of eczema.15 However, deeper 
mechanistic insights are lacking. In the context of psoriasiform lesions, which have 
been shown to be rich in Th1 and Th17 immune cells and to respond to the IL-12/IL-
23p40 blocker ustekinumab,4 there is some evidence that TNF--blockade can lead 
to unopposed interferon/IFN- production by plasmacytoid dendritic cells 
(pDCs),3,10,16-18 which have also been suggested as key drivers in the development 
of conventional psoriasis.19-21 However, sifalimumab, an IFN--blocker, failed to elicit 
effects on psoriasis in a clinical trial,22 challenging the central role of IFN- in this 
disease, at least in fully established lesions. 
Despite the fact that several studies have described potential driver cytokines in anti-
TNF-induced skin lesions,3,4,17,18,23 a comparative, broad immunological 
characterization of anti-TNF--induced inflammatory skin lesions is still lacking. We 
thus decided to comprehensively assess them on a histopathologic, molecular and 
cellular level. We found that anti-TNF--induced “psoriasiform” and 
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“eczematous/spongiotic” skin lesions lack some key immune features of psoriasis 
and eczema, with strong Th1- and IFN-α-associated inflammation. 
 
PATIENTS, MATERIALS AND METHODS 
Patient characteristics and skin samples 
19 patients on anti-TNF-α-treatment were referred to our outpatient clinic due to 
new-onset scaly erythematous skin lesions (Table 1). 17 (89.5%) were treated for 
IBD (15 with Crohn’s disease, 2 with ulcerative colitis), and 2 for rheumatoid arthritis 
(RA). 14, 4 and 1 were on adalimumab, infliximab, or golimumab, respectively. Mean 
age was 40.4 (SD 13.9) years, and the median duration of therapy was 24 months 
(range: 7-105 months). 17/19 patients (89.5%) were negative for ANAs. There was 
neither a prior history of psoriasis nor of eczema (or associated atopy) in any 
individual, and no one reported on injection site reactions. Four-millimeter punch 
biopsies were obtained from clearly inflamed skin without prior topical treatment. 
Biopsies from patients with classic plaque-type psoriasis (n=6), atopic eczema 
(atopic dermatitis, n=9) and from healthy controls (n=5) served as comparators. 
Biopsies were taken under an IRB-approved protocol (Ethics Committee of the 
Medical University of Vienna, Austria; approval #071/2005) according to the 
Declaration of Helsinki. All participants gave written informed consent prior to 
inclusion.  
 
Quantitative RT-PCR 
RNA was isolated with TRI Reagent® (Sigma-Aldrich) and transcribed to cDNA as 
previously described.24 mRNA levels were normalized to the established 
housekeeping gene human β2-microglobulin (B2M),
25 and results depicted as log2 
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fold increase over healthy control skin. Primers and probes for TaqMan qRT-PCR 
assays (Supplementary Table S1) were used from TaqMan Gene Expression 
Assays (Applied Biosystems, Foster City, CA). 
 
Skin samples and histopathologic evaluation 
Formalin-fixed skin specimens were embedded in paraffin, processed, stained with 
hematoxylin and eosin and analyzed by light microscopy. A board-certified 
dermatopathologist analyzed all samples in a blinded fashion. Assessment of 
histopathologic features was performed in a semi-quantitative fashion (Table 2), and 
graded according to a previously described histopathologic psoriasis scoring system 
(HPSS).26,27 
 
Multicolor Immunofluorescence stainings and semi-automated analysis  
Multicolor immunofluorescence stainings were performed on frozen sections,28,29 and 
analyzed using Strataquest V64 (TissueGnostics GmbH, Vienna, Austria) in a semi-
automated fashion (TissueFAXS), as previously established.28 Briefly, a first set of 
analysis layers was applied to automatically differentiate between epidermal, upper 
and lower dermal areas (based on cell density/DAPI staining and background of 
immunofluorescence channels). The detected regions were manually controlled, 
and, if necessary, corrected by adding/substracting areas. NK cells and T cell 
subsets were gated based on mean immunofluorescence intensity of the respective 
channels, and cut-offs were adapted according to isotype controls.  
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Statistical analysis 
B2M normalized mRNA expression values were log2-transformed prior to analysis. 
All analyses were carried out in R (www.R-project.org) and its available packages. 
Differences in expression values (in log2-scale) and cell counts were assessed using 
a linear mixed effect model. Once the model was fitted (using lme function), least 
square means were obtained, and group comparisons were assessed by a two-tailed 
t-test using contrasts (using functions lsmean and contrast in R package lsmeans). 
Condition (AD, Psoriasis, anti-TNF-induced lesion) was considered as fixed factor 
and Subject ID as random effect. With “lsmeans”, Least Squared Means and 
Standard Error of the Mean for each Condition were estimated. The function 
“contrast” was used to estimate and contrast the differences between means 
(individual null hypothesis). The overall null hypothesis was tested by the “test” 
function, which executes a Fisher test. Statistical significance was assigned at 
p≤0.05. False discovery rates (FDR) were calculated using the Benjamini-Hochberg 
procedure (Supplementary Table S2). 
 
RESULTS 
Clinical appearance and histopathologic classification 
We analysed nineteen biopsies from patients with new-onset anti-TNF- related 
inflammatory skin eruptions (Table 1). Affected regions included the trunk, 
extremities, palms, soles, and the scalp. All scalp lesions were clinically 
accompanied by visible hair loss (alopecia). Hematoxylin/eosin (HE) stained 
specimens were assessed by a dermatopathologist for histological reaction patterns. 
Results were grouped according to an established histopathologic psoriasis severity 
score (HPSS)26,27 and compared to findings suggestive of drug eruption (Table 2). 
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Seven lesions showed reaction patterns that were mainly consistent with psoriasis, 
reflected by a HPSS>13,26,27 and were thus classified as “psoriasiform” (n=7). Seven 
samples yielded low HPSS scores, and displayed histopathologic features most 
consistent with spongiotic dermatitis (eczema). Three samples – all from the scalp – 
exhibited a mixed histopathologic reaction pattern with both psoriasiform and 
spongiotic features, consistent with an intermediate HPSS score. Two remaining 
biopsies yielded a low HPSS score and showed a dense lichenoid lymphocytic cell 
infiltrate at the dermo-epidermal junction, and were thus classified as lichenoid. 
Representative images of these 4 reaction patterns are given in Figure 1.  
 
On a molecular level, psoriasiform and spongiotic/eczematous anti-TNF-
induced skin lesions are distinct from both psoriasis and eczema 
As anti-TNF-induced psoriasiform and spongiotic/eczematous skin lesions were 
histopathologically consistent with psoriasis and eczema (spongiotic dermatitis), 
respectively, we assessed these biopsies with an established molecular disease 
classifier.30 This classifier consists of the two inflammatory mediators inducible nitric 
oxide synthase (NOS2 or iNOS) and CCL27, with high NOS2 and low CCL27 mRNA 
levels being characteristic of psoriasis, and low NOS2 and high CCL27 levels being 
characteristic of eczema.30,31 Surprisingly, neither psoriasiform nor 
spongiotic/eczematous anti-TNF-induced lesions showed a molecular pattern 
characteristic of classic psoriasis or eczema (Figure 2A-D). Similarly, neither scalp 
lesions (Figure 2E-F) nor lichenoid lesions (Supplementary Figure S1A-B) showed 
expression levels in the range of psoriasis or eczema. From these data we conclude 
that anti-TNF-induced skin lesions are genuinely different from conventional 
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psoriasis or eczema, even if they show psoriasiform and spongiotic/eczematous 
histological features on conventional H&E staining. 
 
Anti-TNF-induced skin lesions are characterized by strong IFN-γ expression 
across all subtypes 
Next, we assessed 42 immune and barrier markers known to be involved in various 
inflammatory skin diseases30,32 and depicted them in a heat map. Each group 
(psoriasiform, eczematous/spongiotic, scalp, and lichenoid lesions) was compared to 
conventional psoriasis and eczema (Figure 3A-C, Supplementary Figure S1C). In 
line with previous publications,33 conventional psoriasis showed the highest levels of 
Th17-associated molecules (IL-17A, IL-17F, PI3/Elafin, CCL20, IL-19, S100A 
proteins), the antimicrobial peptide DEFB4, and the innate immune marker IL-1B, 
within each comparison (Figure 3A-C, Supplementary Figure S1C). Eczema showed 
highest levels of Th2-associated cytokines (IL-4, IL-13, CCL26, OX40L), the Th9 
cytokine IL-9, and the thymic stromal lymphopoietin (TSLP) receptor, as previously 
described (Figure 3A-C, Supplementary Figure S1C).15 Compared to psoriasis and 
eczema, all forms of anti-TNF--induced lesions showed higher increases in the Th1 
lead cytokine interferon (IFN)-γ and in IFN-γ regulated molecules such as the IL-12 
receptor subunit IL12RB2, and the CXCL9/CXCL10/CXCL11 chemokine receptor 
CXCR3 (Figure 3A-C, Supplementary Figure S1C), which, in turn, is classically 
found on Th1 cells. Across all anti-TNF- lesions, we also found levels of the innate 
immune markers IFN-α1 and the antimicrobial peptide lipocalin (LCN)-2, both 
involved in Th1 priming,34,35 to be higher than in psoriasis and eczema, but with 
lower levels in scalp samples than in psoriasiform or eczematous/spongiotic lesions 
(Figure 3A-C, Supplementary Figure S1C). 
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The strong IFN-γ signature in anti-TNF- lesions is consistent with increased 
numbers of Th1, but not Tc1 or NK cells 
To identify the potential cellular source(s) of the strong IFN-γ signature in anti-TNF- 
lesions, we quantified cells that classically produce this cytokine, namely NK cells, 
type 1 T helper cells (Th1), and type 1 cytotoxic T cells (Tc1),36 using a semi-
automated histology analysis of multicolour immunofluorescence staining.28 In both 
psoriasiform and spongiotic/eczematous lesions we found only very low numbers of 
NK cells, even lower than in healthy control skin (Figure 4A). By contrast, we 
identified a prominent infiltrate of T cells in anti-TNF- lesions (Figure 4B). Among 
these, only Th1 cells (Figure 4C), but not Tc1 cells (Figure 4D) were significantly 
elevated compared to healthy control tissues. Scalp and lichenoid lesions were not 
assessed due to their small sample size.  
 
Distinct cytokine pattern between psoriasiform, eczematous and scalp lesions 
Apart from Th1 activation that was consistently strong in all histologic subtypes, anti-
TNF--induced skin lesions showed some changes specific to the respective 
histologic subtype (Figure 5). Lichenoid eruptions were not assessed due to their 
limited sample size. Psoriasiform lesions showed normal levels of the skin barrier 
protein filaggrin (FLG), as opposed to decreases in eczematous and scalp lesions 
(Figure 5A). While both psoriasiform and eczematous lesions showed increases in 
the pro-inflammatory mediators IL-36A, IL-36G, IL-19, and IL-20, as well as the IFN-
α marker Mx1, scalp lesions lacked upregulation of these mediators (Figure 5B-F). In 
contrast, only eczematous lesions showed upregulation of Th2-associated mediators 
such as IL-13, IL-5, and CCL26 (Figure 5G-I), and showed highest levels of the 
Th22-cytokine IL-22 not only compared to other anti-TNF- lesions (Figure 5J), but 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
also compared to conventional psoriasis and eczema (Figure 3A-C, Supplementary 
Figure S1C).  
 
DISCUSSION 
By characterizing anti-TNF-induced inflammatory skin eruptions, we could stratify 
them into four histopathologic reaction patterns, with highest numbers of 
psoriasiform and eczematous lesions. However, we found that these eruptions are 
distinct from conventional psoriasis and eczema using a molecular disease 
classifier.30,37 Also, biopsies from so-called inflammatory or psoriasiform alopecia of 
the scalp,12 that showed histopathologic characteristics of both psoriasis and 
spongiotic dermatitis, did not meet molecular criteria of either disease. While the 
original classifier used a ratio built of NOS2 and CCL27, we decided to depict 
individual cohorts (fold change over healthy control), in line with the other markers 
investigated.  
Despite their different histological patterns, all anti-TNF--induced lesions were 
unified by high IFN-γ responses that were higher than in conventional eczema or 
psoriasis. This immune axis was also strongly activated in 2 lichenoid samples. 
While the small sample size precluded their further characterization, they at least 
served as positive control for IFN-γ-dependent inflammation.38 
The fact that among potential IFN-γ producing cell types, Th1 cells, but not Tc1 or 
NK cells, were most abundant, suggests the Th1 adaptive immune axis as a likely 
contributor to skin inflammation in these patients. Mechanistically, the strong Th1 
response might be fueled by increases in IFN-α, a type I IFN, consistent with 
published reports.3 TNF-α is thought to be an inhibitor of pDC development and IFN-
α production.18 Consequently, TNF-blockade might disturb a pre-existing cytokine 
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balance between TNF-α and IFN-α in affected skin, favoring pDC derived IFN-α 
secretion.18 This notion is supported by previous reports showing increased staining 
intensities of Mx1 (alias MxA) protein in psoriasiform anti-TNF- lesions,3,17 a 
surrogate marker for type I interferon activity.39 Conversely, it has been shown that 
the administration of IFN-α can induce psoriatic skin lesions,20 and the application of 
imiquimod cream, a potent inducer of IFN-α, can exacerbate psoriasis.40 IFN-α, in 
turn, can facilitate skin homing of T cells by the induction of CXCR3,41 a receptor 
typically found on Th1 cells, which was also increased in all our samples, in line with 
previous reports in psoriasiform lesions.3 In the peripheral blood, it has been shown 
that TNF-blockers increase expression of CXCR3 on circulating T cells in patients 
with rheumatoid arthritis, possibly promoting skin homing of these cells.42 
Furthermore, increases in IL12RB2, a receptor subunit of the pivotal Th1-polarizing 
cytokine IL-12 might be another component of an amplification loop of this type 1 
immune response fueling skin inflammation during TNF-blockade.  
While the role of IFN-α, especially in autoimmune diseases, has traditionally been 
linked to Th1 responses,43 it has now also been associated with priming and 
expansion of Th17 cells.44 Albeit most strongly increased in psoriasis, some Th17-
associated mediators (IL-17A, S100A8, S100A9, S100A12, PI3/Elafin) were also 
upregulated in all anti-TNF-α-induced lesions, suggesting a contribution of the Th17 
immune axis to the formation of these lesions. Importantly, a rare coding variant of 
the IL23R gene, which has previously been associated with increases in Th17 
cytokine production,45 has been described in patients with severe psoriasiform 
and/or anti-TNF-induced alopecia.4 
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It is well established that antimicrobial peptides such as human beta-defensin 2 
(encoded by the DEFB4 gene) or cathelicidin antimicrobial peptide (CAMP)/LL37 are 
upregulated in psoriasis as compared to atopic eczema,46 and they are thought to be 
critically involved in the pathogenesis of psoriasis via triggering autoinflammatory 
immune responses in dendritic cells.21 In psoriasiform and spongiotic/eczematous 
anti-TNF- lesions, CAMP/LL37 was upregulated at even higher levels than in 
psoriasis, mandating further investigation as to their pro-inflammatory contribution in 
these lesions.  
 
Despite this consistent upregulation of Th1-associated mediators across all subsets 
of anti-TNF-induced lesions, we also found several important differences between 
them. In scalp lesions, the IFN-α/Mx1 component was missing. So far, “psoriasiform” 
alopecia has been recognized as part of a spectrum of anti-TNF--induced 
psoriasiform lesions, i.e. psoriasis of the scalp with patchy hair loss.4,47 However, 
scalp lesions did not only lack IFN-α responses, they also showed low IL-19 and IL-
20 levels, two cytokines classically upregulated in psoriasis,33 that were also present 
in our psoriasiform and eczematous lesions. Moreover, scalp lesions lacked IL-36A 
and IL-36G, two IL-1-family cytokines classically upregulated in psoriasis.48,49 It has 
been suggested that in anti-TNF--induced psoriasiform skin lesions, IL-36G 
sustains a proinflammatory self-amplifying loop with IL-17C,23 and that T cell 
stimulation with IL-36 receptor ligands results in the induction of IL-17 and IFN-γ 
responses.50,51 While IL-36A and IL-36G might have a pro-inflammatory role in 
psoriasiform and eczematous lesions outside the scalp, they are likely less relevant 
to anti-TNF-induced scalp lesions. Overall, and despite a small sample size, our data 
consistently demonstrate clear differences distinguishing anti-TNF--induced scalp 
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lesions not only from spongiotic/eczematous lesions, but also from psoriasiform 
lesions in body regions other than the scalp. We are also confident that the lower 
abundance of these cytokines in scalp biopsies was not due to the selection of only 
mildly inflamed lesions, as the same samples showed strong increases in S100A 
proteins, IL-17A, or PI3/Elafin, that were present at even higher levels than in e.g. 
eczema samples.  
Lesions with a spongiotic/eczematous histopathologic reaction pattern differed from 
psoriasiform and from scalp lesions by increases in Th2-associated cytokines (IL-
13/CCL26/IL-5), potentially explaining the eczematous histopathologic features of 
this anti-TNF- subgroup, as these mediators are implicated as key pathogenic 
mediators in eczema.52 Spongiotic/eczematous anti-TNF- lesions also showed the 
highest levels of IL-22 among all groups, including psoriasis and eczema. This 
Th17/Th22 cytokine has been demonstrated to promote epidermal hyperplasia and 
to inhibit epidermal differentiation,53 which makes IL-22 a potential trigger of the 
pathogenic disease phenotype in spongiotic (eczematous) anti-TNF- lesions. 
Psoriasiform lesions, in turn, lacked downregulation of filaggrin (FLG), which is 
considered an important contributor to skin barrier, and has been implicated as being 
central to the development of eczema.54  
 
Our patients, who mostly suffered from IBD, all developed skin lesions for the first 
time during TNF--blockade, limiting the results of this study to this specific patient 
group. Patients with pre-existing eczema and psoriasis can also flare under anti-
TNF- treatment,55-58 but it remains to be determined whether their immune profile is 
similar to new-onset lesions. Another limitation of this pilot study is the small sample 
size, and results need to be confirmed in larger patient cohorts.  
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In sum, we demonstrate that new-onset psoriasiform, eczematous and scalp anti-
TNF-induced skin lesions are distinct immunological entities with characteristic 
Th1/IFN-γ/IFN-α-associated inflammation and major differences from both 
conventional psoriasis and eczema. 
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FIGURE LEGENDS 
Figure 1. Anti-TNF-induced skin lesions. Representative hematoxylin and eosin 
stainings for anti-TNF-induced inflammatory skin lesions showing psoriasiform 
changes (A), spongiotic changes consistent with eczema (B), mixed psoriasiform 
and spongiotic changes found in scalp lesions that showed clinical signs of alopecia 
(C), and lichenoid changes (D). 
 
Figure 2. Anti-TNF-induced skin lesions are different from psoriasis and 
eczema. mRNA levels of NOS2 and CCL27 are shown across histopathologic 
groups of anti-TNF-induced skin lesions. Psoriasiform (A), eczematous (B), and 
scalp lesions (C) are depicted as log2 fold change relative to healthy control skin, 
and compared to levels found in classic psoriasis and eczema (spongiotic 
dermatitis); data are normalized to β2-microglobulin expression; 95%CI boxplot and 
LSmean±SEM; *P≤0.05, **P≤0.01, ***P≤0.001. 
 
Figure 3. RT-PCR heat maps of mRNA expression levels. mRNA levels were 
normalized to β2-microglobulin (B2M), and depicted as color-coded mean log2 fold 
changes (FCH) over healthy control skin; Red color denotes increases, and blue 
color denotes decreases relative to healthy control samples. Heat maps were 
assembled using non-hierarchical clustering. Samples of conventional psoriasis 
(plaque-type psoriasis, n=6) and eczema (atopic dermatitis, n=9) were used as 
comparators for each group of anti-TNF-induced inflammatory skin lesions, which 
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were stratified for histological criteria of psoriasiform (n=7) (A), spongiotic (n=7) (B), 
and scalp lesions (n=3) (C). Large frames denote clusters of maximal expression 
levels in psoriasis (blue), eczema (pink), and anti-TNF-induced lesions (black), 
respectively. Grey solid boxes mark molecules that were maximally upregulated in all 
groups of anti-TNF-induced lesions.  
 
Figure 4. Quantification of interferon gamma (IFN-γ) producing immune cells. 
We assessed numbers of leukocytes in healthy controls (n=10), psoriasis (n=15), 
eczema (n=13), and anti-TNF-induced skin lesions (psoriasiform n=5, eczematous 
n=5), using markers for NK cells (A) and T cells (B). T cells were further divided into 
type 1 T helper cells (C) and type 1 cytotoxic T cells (D), as assessed by the type 1 
transcription factor T-bet; 95%CI boxplot and LSmean±SEM of cell counts per mm 
epidermis; *P≤0.05, **P≤0.01, ***P≤0.001. 
 
Figure 5. Differences between anti-TNF-induced psoriasiform, 
spongiotic/eczematous, and scalp lesions. Selected inflammatory and skin barrier 
molecules are shown for psoriasiform, spongiotic/ezematous, and scalp lesions 
induced by anti-TNF- treatment; 95%CI boxplot and LSmean±SEM of log2 fold 
change in mRNA/B2M relative to healthy control skin; *P≤0.05, **P≤0.01, 
***P≤0.001. 
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SUPPORTING INFORMATION 
Supplementary Figure S1. Lichenoid anti-TNF- lesions in comparison to 
psoriasis and eczema. mRNA levels of NOS2 (A) and CCL27 (B) in lichenoid 
eruptions shown as log2 fold change relative to healthy control skin, compared to 
classic psoriasis and eczema; normalized to β2-microglobulin expression; 95%CI 
boxplot and LSmean±SEM; *P≤0.05, **P≤0.01, ***P≤0.001. RT-PCR heat map (C) of 
mRNA expression levels normalized to β2-microglobulin, depicted as mean log2 fold 
changes (FCH) over healthy control skin, using non-hierarchical clustering. Red 
colour denotes increases, and blue colour denotes decreases relative to healthy 
control samples. Samples of conventional psoriasis (plaque-type psoriasis, n=6) and 
eczema (atopic dermatitis, n=9) were used as comparators for anti-TNF-induced 
lichenoid skin lesions. Large blue, pink and black frames denote clusters of maximal 
expression levels in psoriasis, eczema, and anti-TNF-induced lesions, respectively. 
Grey solid boxes mark molecules that were maximally upregulated in anti-TNF-
induced lesions across all histological groups of anti-TNF-induced lesions.  
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TABLE 1. Baseline characteristics of study patients and histopathologic reaction pattern of anti-TNF-induced skin lesions. 
Sample 
# Diagnosis 
Ongoing TNF-
blocker 
treatment 
Duration of anti-TNF 
therapy at time of 
biopsy (months) 
Duration of 
skin lesions 
(months) ANAs 
Biopsy 
Location 
Overall 
histopathologic 
pattern in biopsy 
1 Ulcerative colitis Adalimumab 59 9 negative Lower Leg Lichenoid 
2 Crohn's Disease Adalimumab 48 6 negative Forearm Psoriasiform 
3 Crohn's Disease Adalimumab 33 2 negative Lower Leg Psoriasiform 
4 Crohn's Disease Adalimumab 7 3 negative Palm Psoriasiform 
5 Crohn's Disease Adalimumab 35 1 negative Palm Spongiotic 
6 Crohn's Disease Adalimumab 8 2 negative Palm Psoriasiform 
7 Crohn's Disease Adalimumab 7 2 negative Scalp Psoriasiform-spongiotic 
8 Crohn's Disease Adalimumab 36 1 negative Scalp Spongiotic-psoriasiform 
9 Crohn's Disease Adalimumab 9 1.5 negative Sole Spongiotic 
10 Crohn's Disease Adalimumab 24 0.5 negative Thigh Lichenoid 
11 Crohn's Disease Adalimumab 12 2 negative Trunk Psoriasiform 
12 Crohn's Disease Adalimumab 11 8 negative Trunk Spongiotic 
13 Rheumatoid Arthritis Adalimumab 105 24 negative Elbow Psoriasiform 
14 Rheumatoid Arthritis Adalimumab 24 4 negative Scalp Spongiotic-psoriasiform 
15 Crohn's Disease Golimumab 11 6 negative Trunk Spongiotic 
16 Ulcerative colitis Infliximab 58 4 positive 1:320 Sole Spongiotic 
17 Crohn's Disease Infliximab 24 3 negative Hand Psoriasiform 
18 Crohn's Disease Infliximab 44 1 negative Trunk Spongiotic 
19 Crohn's Disease Infliximab 36 12 positive 1:160 Trunk Spongiotic 
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TABLE 2. Detailed histopathologic evaluation of anti-TNF-induced skin lesions. 
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Main categories 
(each 0 -12) Subcategories (each 0 - 3)                                       
Epidermal  
Staggered parakeratosis 3 1 1 1 1 2 1 1 2 0 1 0 1 0 1 0 0 0 0 
Epidermal hyperplasia 3 3 2 2 1 2 2 1 2 3 2 0 2 1 1 1 1 3 1 
Hypogranulosis 2 2 2 1 0 1 1 0 1 0 1 2 1 0 1 0 0 1 0 
Mitosis 2 1 2 1 2 0 1 1 0 1 0 0 1 0 0 0 0 0 0 
Vascular 
Dilated vessels 2 2 1 2 2 1 1 2 1 1 1 2 1 2 1 1 1 1 1 
Elongated vessels 2 2 2 1 3 1 1 1 1 1 0 1 0 1 0 0 0 0 1 
Increased number 1 1 2 2 1 1 1 1 0 1 0 1 0 0 0 0 0 0 1 
Contorted vessels 1 1 1 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 
Inflammatory cell 
infiltrate 
Perivascular lymphocytes 1 3 2 1 1 1 2 2 1 1 2 1 1 2 1 1 1 3 1 
Neutrophils intraepidermal 0 0 0 1 0 1 2 2 0 0 1 0 0 1 0 0 0 0 0 
Neutrophils intracorneal 1 1 1 1 1 2 0 1 0 1 1 0 0 0 0 0 0 0 0 
Histiocytes in papillary dermis 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 
HPSS summary (0 - 36) 19 18 17 15 13 13 13 13 10 10 10 9 8 7 6 4 4 9 6 
  Continous hyper/parakeratosis 0 0 1 0 3 0 1 0 1 1 0 0 0 1 0 1 1 0 0 
  Orthohyperkeratosis 0 0 0 0 0 0 0 1 0 1 0 0 1 2 0 0 0 1 2 
  Serumcrust 1 2 0 0 1 0 0 0 0 1 0 0 0 1 1 3 3 0 0 
Other findings 
(n=13) 
Hypergranulosis 0 0 0 0 1 0 1 1 0 0 0 0 0 1 0 1 1 1 1 
Dyskeratosis of epidermal KC 0 0 0 1 1 0 0 0 1 1 3 0 0 0 0 0 0 2 1 
Exocytosis of lymphocytes into 
the epidermis 0 1 1 0 1 0 0 1 1 1 2 1 1 2 2 3 3 2 1 
Spongiosis 1 1 1 1 1 1 0 1 1 1 3 1 1 3 2 3 3 1 0 
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Vacuolar alteration of the basal 
membrane 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 
Edema of the papillary dermis 0 1 1 0 1 1 0 1 2 0 1 0 1 2 1 1 1 1 0 
Lichenoid lymphocytic infiltrate 
at the DEJ 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 3 3 
Eosinophils in the dermis 0 0 0 0 2 0 0 2 2 0 1 0 0 2 1 1 1 1 0 
Extravasated erythrocytes in the 
papillary dermis 0 0 1 0 0 0 0 1 0 0 1 0 1 0 1 1 1 0 0 
Plasma cells in the dermis 0 0 1 1 0 0 1 2 2 0 1 0 0 0 0 1 1 0 1 
Total number of conflicting criteria (max = 13) 2 4 6 3 8 2 3 8 9 6 7 2 5 8 6 9 9 9 6 
Overall pattern 
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Table 2. Histopathologic evaluation of anti-TNF-induced skin lesions. Semiquantitative analysis of major histopathologic 
patterns in anti-TNF-induced skin lesions, grouped for characteristics of psoriasis and drug eruptions, and summarizing the total 
number of criteria conflicting with a diagnosis of psoriasis, whenever applicable; HPSS: histopathologic psoriasis severity score; 
n/a: not applicable; DEJ: Dermo-epidermal junction; KC: keratinocyte. 
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